Free Trial
→ Trump’s treachery (From Porter & Company) (Ad) Buy NAMS Stock  Free NAMS Stock Alerts

NewAmsterdam Pharma (NAMS) Financials

NewAmsterdam Pharma logo
$18.50 -0.85 (-4.38%)
As of 01:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for NewAmsterdam Pharma

Annual Income Statements for NewAmsterdam Pharma

This table shows NewAmsterdam Pharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Net Income / (Loss) Attributable to Common Shareholders		 -242 -177 -30 -32 -7.02
Consolidated Net Income / (Loss)		 -242 -177 -23 -32 -7.02
Net Income / (Loss) Continuing Operations		 -242 -177 -30 -32 -7.02
Total Pre-Tax Income 		-242 -177 -23 -32 -7.02
Total Operating Income		 -176 -183 -3.56 -34 -6.63
Total Gross Profit		 46 14 103 0.01 0.00
Total Revenue		 46 14 103 0.01 0.00
Operating Revenue		 46 14 103 0.01 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 222 197 106 34 6.63
Selling, General & Admin Expense		 70 38 20 5.44 1.69
Research & Development Expense		 151 159 87 28 4.94
Total Other Income / (Expense), net		 -65 6.06 -27 1.39 -0.42
Interest Expense		 0.00 0.00 0.29 0.24 0.42
Interest & Investment Income		 17 11 0.00 - 0.00
Other Income / (Expense), net		 -82 -5.23 -27 1.63 -
Income Tax Expense		 -0.00 0.03 0.00 0.00 0.00
Basic Earnings per Share		 ($2.56) ($2.15) ($1.19) - ($0.76)
Weighted Average Basic Shares Outstanding		 109.82M 89.27M 81.56M - -
Diluted Earnings per Share		 ($2.56) ($2.15) ($1.19) ($1.37) ($0.76)
Weighted Average Diluted Shares Outstanding		 109.82M 89.27M 81.56M - -
Weighted Average Basic & Diluted Shares Outstanding		 109.82M 89.27M 81.56M - -

Quarterly Income Statements for NewAmsterdam Pharma

This table shows NewAmsterdam Pharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Net Income / (Loss) Attributable to Common Shareholders		 -40 -92 -17 -39 -94 -49 -47 -38 -42
Consolidated Net Income / (Loss)		 -40 -92 -17 -39 -94 -49 -47 -38 -42
Net Income / (Loss) Continuing Operations		 -40 -92 -17 -39 -94 -49 -47 -38 -42
Total Pre-Tax Income 		-40 -92 -17 -39 -94 -49 -47 -38 -42
Total Operating Income		 -69 -43 -25 -53 -55 -51 -50 -42 -40
Total Gross Profit		 2.98 13 29 2.28 1.40 0.80 2.94 1.72 8.63
Total Revenue		 2.98 13 29 2.28 1.40 0.80 2.94 1.72 8.63
Operating Revenue		 2.98 13 29 2.28 1.40 0.80 2.94 1.72 8.63
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses		 72 56 54 55 57 52 52 44 48
Selling, General & Admin Expense		 27 21 18 16 14 11 9.13 9.86 8.06
Research & Development Expense		 45 35 36 38 42 41 43 34 40
Total Other Income / (Expense), net		 29 -49 8.36 14 -38 1.61 2.43 4.19 -2.17
Interest & Investment Income		 7.35 4.49 4.44 4.87 3.08 2.67 3.06 4.61 0.94
Other Income / (Expense), net		 22 -53 3.91 8.70 -41 -1.06 -0.63 -0.42 -3.11
Income Tax Expense		 0.00 - -0.00 0.00 0.00 0.03 0.00 0.00 0.00
Basic Earnings per Share		 ($0.34) ($0.91) ($0.18) ($0.41) ($1.06) ($0.60) ($0.57) ($0.47) ($0.51)
Weighted Average Basic Shares Outstanding		 112.27M 109.82M 92.39M 90.02M 89.98M 89.27M - - -
Diluted Earnings per Share		 ($0.34) ($0.91) ($0.18) ($0.41) ($1.06) ($0.60) ($0.57) ($0.47) ($0.51)
Weighted Average Diluted Shares Outstanding		 112.27M 109.82M 92.39M 90.02M 89.98M 89.27M - - -
Weighted Average Basic & Diluted Shares Outstanding		 112.27M 109.82M 92.39M 90.02M 89.98M 89.27M - - -

Annual Cash Flow Statements for NewAmsterdam Pharma

This table details how cash moves in and out of NewAmsterdam Pharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Net Change in Cash & Equivalents		 438 -132 402 50 6.52
Net Cash From Operating Activities		 -159 -141 11 -28 -7.28
Net Cash From Continuing Operating Activities		 -159 -141 11 -28 -7.28
Net Income / (Loss) Continuing Operations		 -242 -177 -23 -32 -7.02
Consolidated Net Income / (Loss)		 -242 -177 -23 -32 -7.02
Depreciation Expense		 0.11 0.05 0.01 0.02 0.00
Amortization Expense		 -0.23 0.00 0.00 - -
Non-Cash Adjustments To Reconcile Net Income		 116 30 23 -0.45 0.39
Changes in Operating Assets and Liabilities, net		 -33 5.87 10 4.32 -0.65
Net Cash From Investing Activities		 -63 -0.02 -0.22 -0.02 0.00
Net Cash From Continuing Investing Activities		 -63 -0.02 -0.22 -0.02 0.00
Purchase of Property, Plant & Equipment		 -0.67 -0.02 -0.22 -0.02 -
Purchase of Investments		 -62 0.00 0.00 - -
Net Cash From Financing Activities		 660 8.91 392 78 14
Net Cash From Continuing Financing Activities		 660 8.91 392 78 14
Repurchase of Common Equity		 -0.54 0.00 0.00 0.00 -
Issuance of Common Equity		 0.00 0.00 397 78 -
Other Financing Activities, net		 660 8.91 -5.05 - -
Cash Interest Paid		 0.00 0.00 0.28 - -
Cash Income Taxes Paid		 0.00 0.03 0.00 - -

Quarterly Cash Flow Statements for NewAmsterdam Pharma

This table details how cash moves in and out of NewAmsterdam Pharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Net Change in Cash & Equivalents		 -27 357 -13 -50 143 -33 -47 -23 -29
Net Cash From Operating Activities		 -36 -37 -13 -54 -55 -33 -47 -29 -32
Net Cash From Continuing Operating Activities		 -36 -37 -13 -54 -55 -33 -47 -29 -32
Net Income / (Loss) Continuing Operations		 -40 -92 -17 -39 -94 -49 -47 -38 -42
Consolidated Net Income / (Loss)		 -40 -92 -17 -39 -94 -49 -47 -38 -42
Depreciation Expense		 0.05 0.05 0.03 0.02 0.02 0.01 0.01 0.01 0.01
Amortization Expense		 -0.51 - - - - - - - -
Non-Cash Adjustments To Reconcile Net Income		 9.20 72 3.60 -9.64 50 6.08 2.98 11 9.31
Changes in Operating Assets and Liabilities, net		 -5.68 -17 0.52 -5.35 -11 10 -2.84 -2.46 0.83
Net Cash From Investing Activities		 2.86 -62 -0.08 -0.21 -0.39 -0.00 -0.01 -0.01 -0.01
Net Cash From Continuing Investing Activities		 2.86 -62 -0.08 -0.21 -0.39 -0.00 -0.01 -0.01 -0.01
Purchase of Property, Plant & Equipment		 -0.02 -0.00 -0.08 -0.21 -0.39 -0.00 -0.01 -0.01 -0.01
Purchase of Investments		 -9.63 - - - - - - - -
Sale and/or Maturity of Investments		 13 - - - - - - - -
Net Cash From Financing Activities		 6.52 457 0.06 4.66 198 - 0.19 6.33 2.39
Net Cash From Continuing Financing Activities		 6.52 457 0.06 4.66 198 - 0.19 6.33 2.39
Repurchase of Common Equity		 -1.59 -0.03 - - -0.52 - - - 0.00
Other Financing Activities, net		 8.11 457 0.06 4.66 199 - 0.19 6.33 2.39

Annual Balance Sheets for NewAmsterdam Pharma

This table presents NewAmsterdam Pharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021
Total Assets		 865 347 569 68
Total Current Assets		 863 347 479 67
Cash & Equivalents		 772 340 469 60
Short-Term Investments		 62 0.00 - -
Prepaid Expenses		 24 6.34 0.16 0.00
Other Current Assets		 4.95 0.00 - -
Plant, Property, & Equipment, net		 0.24 0.05 0.15 0.22
Total Noncurrent Assets		 0.97 0.26 89 0.81
Goodwill		 0.53 0.17 - -
Other Noncurrent Operating Assets		 0.43 0.09 - -
Total Liabilities & Shareholders' Equity		 865 347 569 68
Total Liabilities		 107 59 50 11
Total Current Liabilities		 107 50 38 11
Accounts Payable		 18 28 20 11
Current Deferred Revenue		 6.01 8.94 14 0.00
Other Current Liabilities		 83 13 0.07 0.06
Total Noncurrent Liabilities		 0.20 8.81 12 0.13
Noncurrent Deferred Revenue		 0.00 1.02 4.81 0.00
Other Noncurrent Operating Liabilities		 0.20 7.79 12 0.00
Commitments & Contingencies		 0.00 0.00 - -
Total Equity & Noncontrolling Interests		 758 288 518 56
Total Preferred & Common Equity		 758 288 518 56
Total Common Equity		 758 288 518 56
Common Stock		 1,312 601 641 95
Retained Earnings		 -559 -317 - -
Accumulated Other Comprehensive Income / (Loss)		 4.47 4.42 -128 -39

Quarterly Balance Sheets for NewAmsterdam Pharma

This table presents NewAmsterdam Pharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024
Total Assets		 818 439 447 488
Total Current Assets		 817 438 445 488
Cash & Equivalents		 748 423 431 481
Short-Term Investments		 60 - - -
Prepaid Expenses		 8.83 15 15 6.68
Other Current Assets		 0.00 - - -
Plant, Property, & Equipment, net		 0.24 0.23 0.23 0.10
Total Noncurrent Assets		 0.87 1.09 1.10 0.54
Goodwill		 0.50 0.59 0.54 0.49
Other Noncurrent Operating Assets		 0.37 0.49 0.56 0.05
Total Liabilities & Shareholders' Equity		 818 439 447 488
Total Liabilities		 41 60 59 77
Total Current Liabilities		 41 41 45 60
Accounts Payable		 14 18 15 19
Current Deferred Revenue		 3.03 4.50 6.06 8.12
Other Current Liabilities		 24 19 24 33
Total Noncurrent Liabilities		 0.14 19 14 17
Noncurrent Deferred Revenue		 0.00 0.00 0.22 0.44
Other Noncurrent Operating Liabilities		 0.14 19 14 16
Commitments & Contingencies		 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 777 379 387 412
Total Preferred & Common Equity		 777 379 387 412
Total Common Equity		 777 379 387 412
Common Stock		 1,371 841 833 818
Retained Earnings		 -598 -466 -450 -411
Accumulated Other Comprehensive Income / (Loss)		 4.43 4.42 4.42 4.42

Annual Metrics And Ratios for NewAmsterdam Pharma

This table displays calculated financial ratios and metrics derived from NewAmsterdam Pharma's official financial filings.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Growth Metrics		 - - - - -
Revenue Growth		 223.37% -86.28% 1,008,087.71% 0.00% 0.00%
EBITDA Growth		 -37.44% -525.62% 6.34% -384.22% 0.00%
EBIT Growth		 -37.35% -525.60% 6.36% -384.37% 0.00%
NOPAT Growth		 3.65% -5,043.86% 89.46% -409.00% 0.00%
Net Income Growth		 -36.54% -681.73% 30.07% -360.89% 0.00%
EPS Growth		 -19.07% -80.67% 13.11% -80.82% 0.00%
Operating Cash Flow Growth		 -12.28% -1,424.13% 137.45% -291.24% 0.00%
Free Cash Flow Firm Growth		 -269.23% 51.69% -176.58% 0.00% 0.00%
Invested Capital Growth		 -47.32% -205.66% 1,464.64% 0.00% 0.00%
Revenue Q/Q Growth		 35.63% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -20.91% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 -20.81% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 4.26% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 -21.46% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 -13.78% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -2.86% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 -74.82% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 0.00%
EBITDA Margin		 -567.55% -1,335.30% -29.28% -315,217.31% 0.00%
Operating Margin		 -386.91% -1,298.56% -3.46% -331,406.51% 0.00%
EBIT Margin		 -567.30% -1,335.65% -29.29% -315,372.86% 0.00%
Profit (Net Income) Margin		 -530.25% -1,255.76% -22.04% -317,772.91% 0.00%
Tax Burden Percent		 100.00% 100.02% 100.00% 100.00% 100.00%
Interest Burden Percent		 93.47% 94.00% 75.24% 100.76% 105.89%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -10.91% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -3.29% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 3.03% 0.00% 0.00%
Return on Equity (ROE)		 -46.20% -43.87% -7.88% -57.44% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -112.38% 0.00% 0.00%
Operating Return on Assets (OROA)		 -42.66% -41.10% -9.45% -47.48% 0.00%
Return on Assets (ROA)		 -39.88% -38.64% -7.11% -47.84% 0.00%
Return on Common Equity (ROCE)		 -46.20% -43.87% -7.88% -57.44% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -31.89% -61.35% -4.37% -57.44% 0.00%
Net Operating Profit after Tax (NOPAT)		 -123 -128 -2.49 -24 -4.64
NOPAT Margin		 -270.84% -908.99% -2.42% -231,984.56% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -20.12% -12.07% -7.62% -29.15% 0.00%
Return On Investment Capital (ROIC_SIMPLE)		 -16.29% -44.41% -0.48% - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 154.61% 267.09% 19.00% 53,367.71% 0.00%
R&D to Revenue		 332.30% 1,131.47% 84.47% 278,138.80% 0.00%
Operating Expenses to Revenue		 486.91% 1,398.56% 103.46% 331,506.51% 0.00%
Earnings before Interest and Taxes (EBIT)		 -258 -188 -30 -32 -6.63
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -259 -188 -30 -32 -6.63
Valuation Ratios		 - - - - -
Price to Book Value (P/BV)		 3.13 3.16 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 3.14 3.16 0.00 0.00 0.00
Price to Revenue (P/Rev)		 52.11 64.66 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 33.80 40.49 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.12 -1.00 -0.92 -1.06 0.00
Leverage Ratio		 1.16 1.14 1.11 1.20 0.00
Compound Leverage Factor		 1.08 1.07 0.83 1.21 0.00
Debt to Total Capital		 0.00% 0.00% 0.01% 0.22% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.01% 0.22% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 99.99% 99.78% 0.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 15.60 1.87 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 -0.02 -0.01 0.00
Net Debt to NOPAT		 0.00 0.00 188.39 2.54 0.00
Long-Term Debt to NOPAT		 0.00 0.00 -0.02 -0.01 0.00
Altman Z-Score		 12.51 7.31 0.00 0.00 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - -
Current Ratio		 8.08 6.95 12.64 5.96 0.00
Quick Ratio		 7.80 6.82 12.64 5.96 0.00
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 -99 -27 -55 -20 0.00
Operating Cash Flow to CapEx		 -23,595.83% -588,408.33% 4,825.79% -125,820.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -192.93 -81.89 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 37.16 -116.50 -17.32
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 36.39 -116.59 -17.32
Efficiency Ratios		 - - - - -
Asset Turnover		 0.08 0.03 0.32 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 12.21 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 316.41 140.86 556.47 0.05 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 29.90 234,496.84 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 29.90 234,496.84 0.00
Capital & Investment Metrics		 - - - - -
Invested Capital		 -77 -52 49 -3.61 0.00
Invested Capital Turnover		 -0.71 -10.11 4.50 -0.01 0.00
Increase / (Decrease) in Invested Capital		 -25 -101 53 -3.61 0.00
Enterprise Value (EV)		 1,540 571 0.00 0.00 0.00
Market Capitalization		 2,374 911 0.00 0.00 0.00
Book Value per Share		 $8.20 $3.54 $6.36 $0.00 $0.00
Tangible Book Value per Share		 $8.19 $3.53 $5.26 $0.00 $0.00
Total Capital		 758 288 518 56 0.00
Total Debt		 0.00 0.00 0.06 0.13 0.00
Total Long-Term Debt		 0.00 0.00 0.06 0.13 0.00
Net Debt		 -834 -340 -469 -60 0.00
Capital Expenditures (CapEx)		 0.67 0.02 0.22 0.02 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -78 -44 -28 -4.64 0.00
Debt-free Net Working Capital (DFNWC)		 756 297 441 55 0.00
Net Working Capital (NWC)		 756 297 441 55 0.00
Net Nonoperating Expense (NNE)		 118 49 20 8.74 2.38
Net Nonoperating Obligations (NNO)		 -834 -340 -469 -60 0.00
Total Depreciation and Amortization (D&A)		 -0.11 0.05 0.01 0.02 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 -170.52% -309.13% -26.93% -45,534.23% 0.00%
Debt-free Net Working Capital to Revenue		 1,660.33% 2,107.13% 429.90% 544,388.46% 0.00%
Net Working Capital to Revenue		 1,660.33% 2,107.13% 429.90% 544,388.46% 0.00%
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 ($2.56) ($2.15) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 109.82M 89.27M 0.00 0.00 0.00
Adjusted Diluted Earnings per Share		 ($2.56) ($2.15) $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 109.82M 89.27M 0.00 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 109.82M 89.27M 0.00 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -123 -128 -2.49 -24 -4.64
Normalized NOPAT Margin		 -270.84% -908.99% -2.42% -231,984.56% 0.00%
Pre Tax Income Margin		 -530.25% -1,255.57% -22.04% -317,772.91% 0.00%
Debt Service Ratios		 - - - - -
EBIT to Interest Expense		 0.00 0.00 -104.82 -131.40 -15.78
NOPAT to Interest Expense		 0.00 0.00 -8.68 -96.66 -11.05
EBIT Less CapEx to Interest Expense		 0.00 0.00 -105.59 -131.50 -15.78
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -9.45 -96.75 -11.05
Payout Ratios		 - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.22% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for NewAmsterdam Pharma

This table displays calculated financial ratios and metrics derived from NewAmsterdam Pharma's official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Growth Metrics		 - - - - - - - - -
Revenue Growth		 112.56% 1,490.54% 889.83% 32.73% -83.76% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 51.11% -85.35% 58.02% -2.25% -125.45% 0.00% 0.00% 0.00% 0.00%
EBIT Growth		 51.60% -85.40% 57.98% -2.27% -125.44% 0.00% 0.00% 0.00% 0.00%
NOPAT Growth		 -24.23% 15.36% 49.55% -23.76% -39.22% 0.00% 0.00% 0.00% 0.00%
Net Income Growth		 57.85% -86.24% 64.68% -1.87% -123.16% 0.00% 0.00% 0.00% 0.00%
EPS Growth		 67.92% -51.67% 68.42% 12.77% -107.84% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 33.21% -13.32% 73.39% -84.20% -71.36% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Growth		 -383.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Growth		 55.13% -47.32% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Revenue Q/Q Growth		 -76.68% -56.13% 1,177.36% 62.67% 0.00% -72.70% 71.29% -80.10% 0.00%
EBITDA Q/Q Growth		 51.00% -358.68% 51.97% 54.71% 0.00% -3.88% -16.99% 0.14% 0.00%
EBIT Q/Q Growth		 51.50% -358.31% 51.93% 54.70% 0.00% -3.87% -16.99% 0.13% 0.00%
NOPAT Q/Q Growth		 -59.44% -72.90% 52.44% 5.24% 0.00% -3.06% -16.66% -6.60% 0.00%
Net Income Q/Q Growth		 57.12% -453.72% 57.32% 58.40% 0.00% -5.01% -23.09% 8.87% 0.00%
EPS Q/Q Growth		 62.64% -405.56% 56.10% 61.32% 0.00% -5.26% -21.28% 7.84% 0.00%
Operating Cash Flow Q/Q Growth		 2.70% -199.80% 76.84% 1.14% 0.00% 29.59% -60.30% 8.03% 0.00%
Free Cash Flow Firm Q/Q Growth		 -1,436.75% -121.34% 307.72% -78.80% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 59.43% -74.82% -1.38% 37.60% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -1,589.62% -756.43% -72.35% -1,924.44% -6,911.85% -6,491.03% -1,706.15% -2,498.02% -497.76%
Operating Margin		 -2,314.47% -338.47% -85.89% -2,306.93% -3,960.17% -6,360.40% -1,685.07% -2,474.20% -461.85%
EBIT Margin		 -1,574.14% -756.83% -72.45% -1,925.27% -6,912.92% -6,492.65% -1,706.63% -2,498.78% -497.87%
Profit (Net Income) Margin		 -1,327.30% -721.71% -57.18% -1,711.58% -6,692.86% -6,163.76% -1,602.62% -2,230.11% -486.94%
Tax Burden Percent		 100.00% 100.00% 99.99% 100.00% 100.00% 100.05% 100.00% 100.00% 100.00%
Interest Burden Percent		 84.32% 95.36% 78.93% 88.90% 96.82% 94.88% 93.91% 89.25% 97.81%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -31.51% -46.20% -52.50% -59.21% -55.53% -43.87% 0.00% 0.00% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -113.56% -56.92% -5.54% -32.00% -97.11% -199.79% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -95.75% -54.28% -4.37% -28.45% -94.02% -189.67% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -31.51% -46.20% -52.50% -59.21% -55.53% -43.87% 0.00% 0.00% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -24.10% 0.00% -52.50% -59.21% -55.53% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -48 -30 -18 -37 -39 -36 -35 -30 -28
NOPAT Margin		 -1,620.13% -236.93% -60.12% -1,614.85% -2,772.12% -4,452.28% -1,179.55% -1,731.94% -323.29%
Net Nonoperating Expense Percent (NNEP)		 1.35% -10.54% 0.40% -1.02% -22.83% -4.04% 0.00% 0.00% 0.00%
Return On Investment Capital (ROIC_SIMPLE)		 -6.21% -3.99% - - - -12.40% - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 911.75% 165.25% 63.25% 722.90% 1,031.62% 1,318.18% 310.37% 574.14% 93.43%
R&D to Revenue		 1,502.72% 273.21% 122.64% 1,684.03% 3,028.55% 5,142.22% 1,474.70% 2,000.06% 468.42%
Operating Expenses to Revenue		 2,414.47% 438.47% 185.89% 2,406.93% 4,060.17% 6,460.40% 1,785.07% 2,574.20% 561.85%
Earnings before Interest and Taxes (EBIT)		 -47 -97 -21 -44 -97 -52 -50 -43 -43
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -47 -97 -21 -44 -97 -52 -50 -43 -43
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 2.89 3.13 3.94 4.46 4.68 3.16 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 2.89 3.14 3.95 4.47 4.69 3.16 0.00 0.00 0.00
Price to Revenue (P/Rev)		 47.69 52.11 44.48 232.82 281.10 64.66 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 30.54 33.80 31.90 174.80 210.98 40.49 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.08 -1.12 -1.12 -1.11 -1.17 -1.18 0.00 0.00 0.00
Leverage Ratio		 1.10 1.16 1.16 1.15 1.19 1.14 0.00 0.00 0.00
Compound Leverage Factor		 0.93 1.10 0.92 1.03 1.15 1.08 0.00 0.00 0.00
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 32.84 13.13 14.38 16.86 14.33 8.60 0.00 0.00 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 19.98 8.08 10.61 9.83 8.17 6.95 0.00 0.00 0.00
Quick Ratio		 19.76 7.80 10.25 9.51 8.06 6.82 0.00 0.00 0.00
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -86 -5.63 26 6.47 31 0.00 0.00 0.00 0.00
Operating Cash Flow to CapEx		 -227,925.00% -1,249,366.67% -16,669.33% -25,827.27% -14,182.34% -1,102,466.67% -521,955.56% -586,100.00% -455,185.71%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.07 0.08 0.08 0.02 0.01 0.03 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 278.11 316.41 145.43 31.73 67.94 140.86 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 -31 -77 -44 -43 -69 -52 0.00 0.00 0.00
Invested Capital Turnover		 -0.94 -0.71 -1.53 -0.34 -0.20 -0.27 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 38 -25 -44 -43 -69 0.00 0.00 0.00 0.00
Enterprise Value (EV)		 1,439 1,540 1,072 1,298 1,448 571 0.00 0.00 0.00
Market Capitalization		 2,248 2,374 1,494 1,728 1,929 911 754 970 1,081
Book Value per Share		 $7.08 $8.20 $4.21 $4.31 $4.58 $3.54 $0.00 $0.00 $0.00
Tangible Book Value per Share		 $7.07 $8.19 $4.20 $4.30 $4.57 $3.53 $0.00 $0.00 $0.00
Total Capital		 777 758 379 387 412 288 0.00 0.00 0.00
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -808 -834 -423 -431 -481 -340 0.00 0.00 0.00
Capital Expenditures (CapEx)		 0.02 0.00 0.08 0.21 0.39 0.00 0.01 0.01 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -32 -78 -26 -31 -53 -44 0.00 0.00 0.00
Debt-free Net Working Capital (DFNWC)		 776 756 397 400 428 297 0.00 0.00 0.00
Net Working Capital (NWC)		 776 756 397 400 428 297 0.00 0.00 0.00
Net Nonoperating Expense (NNE)		 -8.72 62 -0.86 2.20 55 14 12 8.55 14
Net Nonoperating Obligations (NNO)		 -808 -834 -423 -431 -481 -340 0.00 0.00 0.00
Total Depreciation and Amortization (D&A)		 -0.46 0.05 0.03 0.02 0.02 0.01 0.01 0.01 0.01
Debt-free, Cash-free Net Working Capital to Revenue		 -68.07% -170.52% -77.72% -413.03% -773.11% -309.13% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 1,646.99% 1,660.33% 1,180.62% 5,388.54% 6,238.65% 2,107.13% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 1,646.99% 1,660.33% 1,180.62% 5,388.54% 6,238.65% 2,107.13% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.34) ($0.91) ($0.18) ($0.41) ($1.06) ($0.60) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 112.27M 109.82M 92.39M 90.02M 89.98M 89.27M 0.00 0.00 0.00
Adjusted Diluted Earnings per Share		 ($0.34) ($0.91) ($0.18) ($0.41) ($1.06) ($0.60) $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 112.27M 109.82M 92.39M 90.02M 89.98M 89.27M 0.00 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 112.27M 109.82M 92.39M 90.02M 89.98M 89.27M 0.00 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -48 -30 -18 -37 -39 -36 -35 -30 -28
Normalized NOPAT Margin		 -1,620.13% -236.93% -60.12% -1,614.85% -2,772.12% -4,452.28% -1,179.55% -1,731.94% -323.29%
Pre Tax Income Margin		 -1,327.30% -721.71% -57.19% -1,711.58% -6,692.86% -6,160.40% -1,602.62% -2,230.11% -486.94%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.86% -0.22% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About NewAmsterdam Pharma's Financials

When does NewAmsterdam Pharma's financial year end?

According to the most recent income statement we have on file, NewAmsterdam Pharma's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has NewAmsterdam Pharma's net income changed over the last 4 years?

NewAmsterdam Pharma's net income appears to be on an upward trend, with a most recent value of -$241.60 million in 2024, rising from -$7.02 million in 2020. The previous period was -$176.94 million in 2023. Check out NewAmsterdam Pharma's forecast to explore projected trends and price targets.

What is NewAmsterdam Pharma's operating income?
NewAmsterdam Pharma's total operating income in 2024 was -$176.29 million, based on the following breakdown:
  • Total Gross Profit: $45.56 million
  • Total Operating Expenses: $221.85 million
How has NewAmsterdam Pharma revenue changed over the last 4 years?

Over the last 4 years, NewAmsterdam Pharma's total revenue changed from $0.00 in 2020 to $45.56 million in 2024, a change of 4,556,300,000.0%.

How much debt does NewAmsterdam Pharma have?

NewAmsterdam Pharma's total liabilities were at $107.12 million at the end of 2024, a 82.5% increase from 2023, and a 847.3% increase since 2021.

How much cash does NewAmsterdam Pharma have?

In the past 3 years, NewAmsterdam Pharma's cash and equivalents has ranged from $60.09 million in 2021 to $771.74 million in 2024, and is currently $771.74 million as of their latest financial filing in 2024.

How has NewAmsterdam Pharma's book value per share changed over the last 4 years?

Over the last 4 years, NewAmsterdam Pharma's book value per share changed from 0.00 in 2020 to 8.20 in 2024, a change of 819.9%.


Related Companies

This page (NASDAQ:NAMS) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
Elon Set to Shock the World on June 1st?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...
Brownstone Research | Sponsored
Massive new energy source found in Utah
NEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...
Stansberry Research | Sponsored
Why Elon put $51 million into this
Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists
True Market Insiders | Sponsored
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
Gold Alert: The Truth About Fort Knox Is Coming
Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...
Golden Portfolio | Sponsored
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
The July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...
Crypto Swap Profits | Sponsored